Twist bioscience and centogene to develop advanced sequencing tools to make genetic testing rapidly accessible for more patients with rare diseases

South san francisco, calif.--(business wire)--twist bioscience corporation (nasdaq: twst), a company enabling customers to succeed through its offering of high-quality synthetic dna using its silicon platform, and centogene n.v. (nasdaq: cntg), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that they have signed a contract to collaborate on the development and commercialization of custom assay kits for rare
CNTG Ratings Summary
CNTG Quant Ranking